Solid Tumors, with a Focus on Urological Cancers: From Molecular Mechanisms to Predictive Biomarkers

Dear Colleagues,

Solid tumors, including urological cancers (e.g., prostate, bladder, and kidney cancers) and other malignancies, remain a significant global health challenge due to their complexity and resistance to current therapies. Central to their development and progression is the tumor microenvironment (TME), a dynamic ecosystem composed of cancer cells, immune infiltrates, stromal components, vasculature, and the extracellular matrix. The TME not only drives tumor initiation, progression, and metastasis but also contributes to immune evasion and therapy resistance, making it a critical area for research and therapeutic innovation.

With recent advances in single-cell multi-omics, spatial transcriptomics, and other cutting-edge technologies, researchers are now able to dissect the intricate molecular and cellular mechanisms driving tumor behavior and identify predictive biomarkers and novel therapeutic targets across different types of solid tumors. By linking molecular discoveries to translational research, these advances provide opportunities to develop personalized medicine and combination therapies that improve patient outcomes.

This Special Issue invites submissions of high-quality research covering the molecular mechanisms underlying the development of solid tumors, with a special focus on urological cancers. Contributions exploring TME dynamics, predictive biomarkers, therapeutic innovations, and the application of advanced technologies are particularly welcome. Research on other solid tumor types that aligns with this translational focus is also encouraged.

Prof. Dr. Linhui Wang
Dr. Aimin Jiang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.